Brief: Atea Pharmaceuticals Provides Update On Global Phase 3 Sunrise-3 Trial Evaluating Bemnifosbuvir For Treatment Of Covid-19
13/09/2024 12:32
Sept 13 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS PROVIDES UPDATE ON GLOBAL PHASE 3
SUNRISE-3
TRIAL EVALUATING BEMNIFOSBUVIR FOR TREATMENT OF COVID-19
* ATEA PHARMACEUTICALS INC - SUNRISE-3 TRIAL DID NOT MEET
PRIMARY
ENDPOINT
* ATEA PHARMACEUTICALS INC - BEMNIFOSBUVIR GENERALLY SAFE
AND WELL
TOLERATED IN TRIAL
* ATEA PHARMACEUTICALS INC - ADDITIONAL PHASE 2 RESULTS
EXPECTED
IN Q4 2024
Source text for Eikon: ID:nGNX8hYY7B
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM